A phase 1 study of the antibody‐drug conjugate brentuximab vedotin with re‐induction chemotherapy in patients with CD30‐expressing relapsed/refractory acute myeloid leukemia
Narayan, Rupa, Blonquist, Traci M., Emadi, Ashkan, Hasserjian, Robert P., Burke, Meghan, Lescinskas, Christopher, Neuberg, Donna S., Brunner, Andrew M., Hobbs, Gabriela, Hock, Hanno, McAfee, Steven L.Journal:
Cancer
DOI:
10.1002/cncr.32657
Date:
December, 2019
File:
PDF, 334 KB
2019